Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab and Pegaspargase in Relapsed/Refractory Extranodal NK/T-cell Lymphoma
NCT04337593Phase 2Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of basiliximab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Status: unknown.
02
Drugs
basiliximab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04337593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337593.